Mineralys Therapeutics CEO Set to Ignite Discussion at Guggenheim Biotech Conference

Mineralys Therapeutics

RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) announced this week that its Chief Executive Officer, Jon Congleton, will participate in a fireside chat at the upcoming Guggenheim Securities 6th Annual Biotechnology Conference. The event is scheduled to take place in New York City on February 7-8, 2024.

The fireside chat featuring Congleton is slated for 9:00 am EST on Thursday, February 8, 2024. This format, known for fostering engaging and insightful discussions, promises an in-depth look into the operations and future direction of Mineralys Therapeutics.

Mineralys Therapeutics, a Pennsylvania-based company, is a leader in the biopharmaceutical field. Its participation in this prestigious conference underscores the company’s commitment to advancing knowledge and fostering collaboration within the industry.

Those unable to attend the Guggenheim Securities 6th Annual Biotechnology Conference in person can still partake in the conversation. A live webcast of Congleton’s fireside chat will be available under the “News and Events” section of the Investor Relations page on the Mineralys website. For those who miss the live webcast, a replay will be accessible on the company’s website for approximately 90 days thereafter.

The Guggenheim Securities Biotechnology Conference brings together key players in the biopharmaceutical industry, offering a platform for the exchange of ideas and updates on recent advancements. The inclusion of Mineralys Therapeutics’ CEO in this year’s event highlights the company’s significance in the sector and its potential for future contributions to the field of biotechnology.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.